Disease Overview
Colorectal cancer (CRC) is one of the big four tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.
Market Snapshot
Colorectal cancer (CRC) is one of the big four tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.
Market Snapshot
- Avastin will remain the leading targeted therapy in the colorectal cancer market through to 2025.
- Avastin in combination with FOLFOX remains the most commonly prescribed first-line treatment for Stage IV disease.
- By 2037, diagnosed incident cases of colorectal cancer are forecast to increase by 27.3% to 672,400 cases.
- A number of leading drugs will soon face biosimilar competition.
- Pipeline candidates will use novel mechanisms of action as distinguishing factors in an increasingly crowded market.
Table of Contents
FORECAST: COLORECTAL CANCER (Published on 11 December 2017)
Overview
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Avastin
Product Profile (Late Stage): Cotellic
Product Profile: Cyramza
Product Profile: Erbitux
Product Profile: Keytruda
Product Profile: Lonsurf
Product Profile (Late Stage): Oncovax
Product Profile: Opdivo
Product Profile: Stivarga
Product Profile: Ts-1
Product Profile (Late Stage): Tecentriq
Product Profile: Vectibix
Product Profile: Zaltrap
Product Profile (Late Stage): Binimetinib
Product Profile (Late Stage): Lefitolimod
Product Profile (Late Stage): Masitinib
Product Profile (Late Stage): Napabucasin
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Avastin
Product Profile (Late Stage): Cotellic
Product Profile: Cyramza
Product Profile: Erbitux
Product Profile: Keytruda
Product Profile: Lonsurf
Product Profile (Late Stage): Oncovax
Product Profile: Opdivo
Product Profile: Stivarga
Product Profile: Ts-1
Product Profile (Late Stage): Tecentriq
Product Profile: Vectibix
Product Profile: Zaltrap
Product Profile (Late Stage): Binimetinib
Product Profile (Late Stage): Lefitolimod
Product Profile (Late Stage): Masitinib
Product Profile (Late Stage): Napabucasin
TREATMENT: COLORECTAL CANCER (Published on 25 August 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
EPIDEMIOLOGY: COLORECTAL CANCER (Published on 06 September 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix
Disease Background
Methodology
Forecast
Bibliography
Appendix
MARKETED DRUGS: COLORECTAL CANCER (Published on 11 December 2017)
Overview
Executive Summary
Product Overview
Product Profile: Avastin
Product Profile: Cyramza
Product Profile: Erbitux
Product Profile: Keytruda
Product Profile: Lonsurf
Product Profile: Opdivo
Product Profile: Stivarga
Product Profile: Ts-1
Product Profile: Vectibix
Product Profile: Zaltrap
Executive Summary
Product Overview
Product Profile: Avastin
Product Profile: Cyramza
Product Profile: Erbitux
Product Profile: Keytruda
Product Profile: Lonsurf
Product Profile: Opdivo
Product Profile: Stivarga
Product Profile: Ts-1
Product Profile: Vectibix
Product Profile: Zaltrap
PIPELINE: COLORECTAL CANCER (Published on 11 December 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Cotellic
Product Profile (Late Stage): Oncovax
Product Profile (Late Stage): Tecentriq
Product Profile (Late Stage): Binimetinib
Product Profile (Late Stage): Encorafenib
Product Profile (Late Stage): Lefitolimod
Product Profile (Late Stage): Masitinib
Product Profile (Late Stage): Napabucasin
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Cotellic
Product Profile (Late Stage): Oncovax
Product Profile (Late Stage): Tecentriq
Product Profile (Late Stage): Binimetinib
Product Profile (Late Stage): Encorafenib
Product Profile (Late Stage): Lefitolimod
Product Profile (Late Stage): Masitinib
Product Profile (Late Stage): Napabucasin
LIST OF FIGURES
Figure 1: Colorectal cancer – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for colorectal cancer
Figure 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Second- and third-line pipeline colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand, 2016–25
Figure 5: PD-1/PD-L1 drug sales in colorectal cancer across the US, Japan, and five major EU markets, by brand, 2016–25
Figure 6: Colorectal cancer sales across the US, Japan, and five major EU markets, by class, 2016–25
Figure 7: Patient-based forecast methodology for colorectal cancer
Figure 8: Price sources and calculations, by country
Figure 9: Avastin for colorectal cancer – SWOT analysis
Figure 10: The authors drug assessment summary of Avastin for colorectal cancer
Figure 11: The authors drug assessment summary of Avastin for colorectal cancer
Figure 12: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: Cotellic for colorectal cancer – SWOT analysis
Figure 14: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 15: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 16: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 17: Cyramza for colorectal cancer – SWOT analysis
Figure 18: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 19: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 21: Erbitux for colorectal cancer – SWOT analysis
Figure 22: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 23: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 24: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 25: Keytruda for colorectal cancer – SWOT analysis
Figure 26: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 27: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 28: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 29: Lonsurf for colorectal cancer – SWOT analysis
Figure 30: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 31: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 32: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 33: OncoVAX for colon cancer – SWOT analysis
Figure 34: The authors drug assessment summary of OncoVAX for colon cancer
Figure 35: The authors drug assessment summary of OncoVAX for colon cancer
Figure 36: OncoVAX sales for colon cancer in the US, 2016–25
Figure 37: Opdivo for colorectal cancer – SWOT analysis
Figure 38: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 39: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 40: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 41: Stivarga for colorectal cancer – SWOT analysis
Figure 42: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 43: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 44: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 45: TS-1 for colorectal cancer – SWOT analysis
Figure 46: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 47: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 48: TS-1 sales for colorectal cancer in Japan, 2016–25
Figure 49: Tecentriq for colorectal cancer – SWOT analysis
Figure 50: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 51: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 52: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 53: Vectibix for colorectal cancer – SWOT analysis
Figure 54: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 55: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 56: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 57: Zaltrap for colorectal cancer – SWOT analysis
Figure 58: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 59: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 60: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 61: Binimetinib for colorectal cancer – SWOT analysis
Figure 62: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 63: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 64: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 65: Lefitolimod for colorectal cancer – SWOT analysis
Figure 66: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 67: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 68: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 69: Masitinib for colorectal cancer – SWOT analysis
Figure 70: The authors drug assessment summary for masitinib in colorectal cancer
Figure 71: The authors drug assessment summary for masitinib in colorectal cancer
Figure 72: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 73: Napabucasin for colorectal cancer – SWOT analysis
Figure 74: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 75: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 76: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 77: Distribution of colorectal cancer patients across the US, Japan, and five major EU markets, by stage (%)
Figure 78: Percentage of Stage I and Stage II colorectal cancer patients receiving each type of treatment, by country
Figure 79: Percentage of Stage III colorectal cancer patients receiving each type of treatment, by country
Figure 80: Percentage of Stage III colorectal cancer patients treated with surgery and systemic therapy who receive neoadjuvant or adjuvant therapy, by country
Figure 81: Top three regimens used in the adjuvant treatment of Stage III colorectal cancer patients, by country
Figure 82: Percentage of Stage IV colorectal cancer patients receiving each treatment type, by country
Figure 83: Top three regimens used in the first-line treatment of Stage IV colorectal cancer patients receiving systemic therapy without surgery, by country
Figure 84: Top three regimens used in the first-line maintenance treatment of Stage IV colorectal cancer patients, by country
Figure 85: Percentage of Stage IV colorectal cancer patients currently receiving each line of therapy, by country
Figure 86: Top three regimens used for second-line treatment of Stage IV colorectal cancer patients, by country
Figure 87: Top three regimens used for third-line treatment of Stage IV colorectal cancer patients, by country
Figure 88: Percentage of local relapse colorectal cancer patients receiving each treatment type, by country
Figure 89: Top three regimens used in the adjuvant treatment of local relapse colorectal cancer patients, by country
Figure 90: Percentage of distant relapse colorectal cancer patients receiving each treatment type, by country
Figure 91: Top three regimens used in the first-line treatment of distant relapse CRC patients receiving systemic therapy without surgery, by country
Figure 92: Trends in incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017–37
Figure 93: Avastin for colorectal cancer – SWOT analysis
Figure 94: The authors drug assessment summary of Avastin for colorectal cancer
Figure 95: The authors drug assessment summary of Avastin for colorectal cancer
Figure 96: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 97: Cyramza for colorectal cancer – SWOT analysis
Figure 98: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 99: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 100: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 101: Erbitux for colorectal cancer – SWOT analysis
Figure 102: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 103: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 104: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 105: Keytruda for colorectal cancer – SWOT analysis
Figure 106: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 107: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 108: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 109: Lonsurf for colorectal cancer – SWOT analysis
Figure 110: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 111: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 112: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 113: Opdivo for colorectal cancer – SWOT analysis
Figure 114: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 115: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 116: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 117: Stivarga for colorectal cancer – SWOT analysis
Figure 118: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 119: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 120: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 121: TS-1 for colorectal cancer – SWOT analysis
Figure 122: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 123: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 124: TS-1 sales for colorectal cancer in Japan, 2016–25
Figure 125: Vectibix for colorectal cancer – SWOT analysis
Figure 126: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 127: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 128: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 129: Zaltrap for colorectal cancer – SWOT analysis
Figure 130: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 131: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 132: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 133: Cotellic for colorectal cancer – SWOT analysis
Figure 134: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 135: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 136: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 137: OncoVAX for colon cancer – SWOT analysis
Figure 138: The authors drug assessment summary of OncoVAX for colon cancer
Figure 139: The authors drug assessment summary of OncoVAX for colon cancer
Figure 140: OncoVAX sales for colon cancer in the US, 2016–25
Figure 141: Tecentriq for colorectal cancer – SWOT analysis
Figure 142: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 143: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 144: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 145: Binimetinib for colorectal cancer – SWOT analysis
Figure 146: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 147: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 148: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 149: Encorafenib for colorectal cancer – SWOT analysis
Figure 150: The authors drug assessment summary for encorafenib in colorectal cancer
Figure 151: The authors drug assessment summary for encorafenib in colorectal cancer
Figure 152: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 153: Lefitolimod for colorectal cancer – SWOT analysis
Figure 154: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 155: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 156: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 157: Masitinib for colorectal cancer – SWOT analysis
Figure 158: The authors drug assessment summary for masitinib in colorectal cancer
Figure 159: The authors drug assessment summary for masitinib in colorectal cancer
Figure 160: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 161: Napabucasin for colorectal cancer – SWOT analysis
Figure 162: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 163: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 164: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: The authors assessment summary of key marketed and pipeline drugs for colorectal cancer
Figure 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Second- and third-line pipeline colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand, 2016–25
Figure 5: PD-1/PD-L1 drug sales in colorectal cancer across the US, Japan, and five major EU markets, by brand, 2016–25
Figure 6: Colorectal cancer sales across the US, Japan, and five major EU markets, by class, 2016–25
Figure 7: Patient-based forecast methodology for colorectal cancer
Figure 8: Price sources and calculations, by country
Figure 9: Avastin for colorectal cancer – SWOT analysis
Figure 10: The authors drug assessment summary of Avastin for colorectal cancer
Figure 11: The authors drug assessment summary of Avastin for colorectal cancer
Figure 12: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: Cotellic for colorectal cancer – SWOT analysis
Figure 14: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 15: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 16: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 17: Cyramza for colorectal cancer – SWOT analysis
Figure 18: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 19: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 21: Erbitux for colorectal cancer – SWOT analysis
Figure 22: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 23: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 24: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 25: Keytruda for colorectal cancer – SWOT analysis
Figure 26: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 27: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 28: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 29: Lonsurf for colorectal cancer – SWOT analysis
Figure 30: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 31: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 32: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 33: OncoVAX for colon cancer – SWOT analysis
Figure 34: The authors drug assessment summary of OncoVAX for colon cancer
Figure 35: The authors drug assessment summary of OncoVAX for colon cancer
Figure 36: OncoVAX sales for colon cancer in the US, 2016–25
Figure 37: Opdivo for colorectal cancer – SWOT analysis
Figure 38: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 39: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 40: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 41: Stivarga for colorectal cancer – SWOT analysis
Figure 42: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 43: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 44: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 45: TS-1 for colorectal cancer – SWOT analysis
Figure 46: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 47: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 48: TS-1 sales for colorectal cancer in Japan, 2016–25
Figure 49: Tecentriq for colorectal cancer – SWOT analysis
Figure 50: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 51: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 52: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 53: Vectibix for colorectal cancer – SWOT analysis
Figure 54: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 55: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 56: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 57: Zaltrap for colorectal cancer – SWOT analysis
Figure 58: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 59: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 60: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 61: Binimetinib for colorectal cancer – SWOT analysis
Figure 62: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 63: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 64: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 65: Lefitolimod for colorectal cancer – SWOT analysis
Figure 66: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 67: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 68: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 69: Masitinib for colorectal cancer – SWOT analysis
Figure 70: The authors drug assessment summary for masitinib in colorectal cancer
Figure 71: The authors drug assessment summary for masitinib in colorectal cancer
Figure 72: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 73: Napabucasin for colorectal cancer – SWOT analysis
Figure 74: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 75: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 76: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 77: Distribution of colorectal cancer patients across the US, Japan, and five major EU markets, by stage (%)
Figure 78: Percentage of Stage I and Stage II colorectal cancer patients receiving each type of treatment, by country
Figure 79: Percentage of Stage III colorectal cancer patients receiving each type of treatment, by country
Figure 80: Percentage of Stage III colorectal cancer patients treated with surgery and systemic therapy who receive neoadjuvant or adjuvant therapy, by country
Figure 81: Top three regimens used in the adjuvant treatment of Stage III colorectal cancer patients, by country
Figure 82: Percentage of Stage IV colorectal cancer patients receiving each treatment type, by country
Figure 83: Top three regimens used in the first-line treatment of Stage IV colorectal cancer patients receiving systemic therapy without surgery, by country
Figure 84: Top three regimens used in the first-line maintenance treatment of Stage IV colorectal cancer patients, by country
Figure 85: Percentage of Stage IV colorectal cancer patients currently receiving each line of therapy, by country
Figure 86: Top three regimens used for second-line treatment of Stage IV colorectal cancer patients, by country
Figure 87: Top three regimens used for third-line treatment of Stage IV colorectal cancer patients, by country
Figure 88: Percentage of local relapse colorectal cancer patients receiving each treatment type, by country
Figure 89: Top three regimens used in the adjuvant treatment of local relapse colorectal cancer patients, by country
Figure 90: Percentage of distant relapse colorectal cancer patients receiving each treatment type, by country
Figure 91: Top three regimens used in the first-line treatment of distant relapse CRC patients receiving systemic therapy without surgery, by country
Figure 92: Trends in incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017–37
Figure 93: Avastin for colorectal cancer – SWOT analysis
Figure 94: The authors drug assessment summary of Avastin for colorectal cancer
Figure 95: The authors drug assessment summary of Avastin for colorectal cancer
Figure 96: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 97: Cyramza for colorectal cancer – SWOT analysis
Figure 98: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 99: The authors drug assessment summary of Cyramza for colorectal cancer
Figure 100: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 101: Erbitux for colorectal cancer – SWOT analysis
Figure 102: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 103: The authors drug assessment summary of Erbitux for colorectal cancer
Figure 104: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 105: Keytruda for colorectal cancer – SWOT analysis
Figure 106: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 107: The authors drug assessment summary for Keytruda in colorectal cancer
Figure 108: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 109: Lonsurf for colorectal cancer – SWOT analysis
Figure 110: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 111: The authors drug assessment summary of Lonsurf for colorectal cancer
Figure 112: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 113: Opdivo for colorectal cancer – SWOT analysis
Figure 114: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 115: The authors drug assessment summary of Opdivo for colorectal cancer
Figure 116: Opdivo sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 117: Stivarga for colorectal cancer – SWOT analysis
Figure 118: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 119: The authors drug assessment summary of Stivarga for colorectal cancer
Figure 120: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 121: TS-1 for colorectal cancer – SWOT analysis
Figure 122: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 123: The authors drug assessment summary of TS-1 in colorectal cancer
Figure 124: TS-1 sales for colorectal cancer in Japan, 2016–25
Figure 125: Vectibix for colorectal cancer – SWOT analysis
Figure 126: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 127: The authors drug assessment summary of Vectibix for colorectal cancer
Figure 128: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 129: Zaltrap for colorectal cancer – SWOT analysis
Figure 130: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 131: The authors drug assessment summary of Zaltrap for colorectal cancer
Figure 132: Zaltrap sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 133: Cotellic for colorectal cancer – SWOT analysis
Figure 134: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 135: The authors drug assessment summary of Cotellic for colorectal cancer
Figure 136: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 137: OncoVAX for colon cancer – SWOT analysis
Figure 138: The authors drug assessment summary of OncoVAX for colon cancer
Figure 139: The authors drug assessment summary of OncoVAX for colon cancer
Figure 140: OncoVAX sales for colon cancer in the US, 2016–25
Figure 141: Tecentriq for colorectal cancer – SWOT analysis
Figure 142: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 143: The authors drug assessment summary of Tecentriq for colorectal cancer
Figure 144: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 145: Binimetinib for colorectal cancer – SWOT analysis
Figure 146: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 147: The authors drug assessment summary for binimetinib in colorectal cancer
Figure 148: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 149: Encorafenib for colorectal cancer – SWOT analysis
Figure 150: The authors drug assessment summary for encorafenib in colorectal cancer
Figure 151: The authors drug assessment summary for encorafenib in colorectal cancer
Figure 152: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 153: Lefitolimod for colorectal cancer – SWOT analysis
Figure 154: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 155: The authors drug assessment summary for lefitolimod in colorectal cancer
Figure 156: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 157: Masitinib for colorectal cancer – SWOT analysis
Figure 158: The authors drug assessment summary for masitinib in colorectal cancer
Figure 159: The authors drug assessment summary for masitinib in colorectal cancer
Figure 160: Masitinib sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
Figure 161: Napabucasin for colorectal cancer – SWOT analysis
Figure 162: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 163: The authors drug assessment summary for napabucasin in colorectal cancer
Figure 164: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
Table 1: Colorectal cancer sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: PD-1/PD-L1 colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by brand and class ($m), 2016–25
Table 4: Summary of drug classes and molecules included in The authors colorectal cancer patient-based forecast
Table 5: Exchange rates used for calculating prices
Table 6: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
Table 7: Avastin drug profile
Table 8: Overview of major approvals for Avastin in colorectal cancer
Table 9: Avastin Phase III data in colorectal cancer
Table 10: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
Table 12: Cotellic drug profile
Table 13: Cotellic Phase III trial in colorectal cancer
Table 14: Cotellic early-phase data in colorectal cancer
Table 15: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 16: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
Table 17: Cyramza drug profile
Table 18: Cyramza Phase III data in colorectal cancer
Table 19: Cyramza Phase I trials in colorectal cancer
Table 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 21: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 22: Erbitux drug profile
Table 23: Overview of major approvals for Erbitux in colorectal cancer
Table 24: Erbitux Phase III data in colorectal cancer
Table 25: Erbitux Phase III data in colorectal cancer
Table 26: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 27: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
Table 28: Keytruda drug profile
Table 29: Keytruda Phase III trial in colorectal cancer
Table 30: Keytruda early-phase data in colorectal cancer
Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
Table 33: Lonsurf drug profile
Table 34: Lonsurf Phase III data in colorectal cancer
Table 35: Lonsurf Phase II trials in colorectal cancer
Table 36: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 37: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
Table 38: OncoVAX drug profile
Table 39: OncoVAX Phase III trial in colon cancer
Table 40: OncoVAX Phase III data in colon cancer
Table 41: OncoVAX sales for colon cancer in the US ($m), 2016–25
Table 42: Patients treated with OncoVAX in the US, 2016–25
Table 43: Opdivo drug profile
Table 44: Opdivo pivotal trial data in colorectal cancer
Table 45: Opdivo early-phase trials in colorectal cancer
Table 46: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 47: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
Table 48: Stivarga drug profile
Table 49: Stivarga pivotal trial data in colorectal cancer
Table 50: Stivarga ongoing trials in colorectal cancer
Table 51: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 52: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25
Table 53: TS-1 drug profile
Table 54: TS-1 pivotal trial data in colorectal cancer
Table 55: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
Table 56: Patients treated with TS-1 in Japan, 2016–25
Table 57: Tecentriq drug profile
Table 58: Tecentriq Phase III trial in colorectal cancer
Table 59: Tecentriq early-phase data in colorectal cancer
Table 60: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 61: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
Table 62: Vectibix drug profile
Table 63: Overview of major approvals for Vectibix in colorectal cancer
Table 64: Vectibix pivotal trial data in colorectal cancer
Table 65: Vectibix early-phase data in colorectal cancer
Table 66: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 67: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
Table 68: Zaltrap drug profile
Table 69: Zaltrap pivotal trial data in colorectal cancer
Table 70: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 71: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016–25
Table 72: Binimetinib drug profile
Table 73: Binimetinib Phase III data in colorectal cancer
Table 74: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 75: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
Table 76: Lefitolimod drug profile
Table 77: Lefitolimod Phase III trial in colorectal cancer
Table 78: Lefitolimod Phase II data in colorectal cancer
Table 79: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 80: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016–25
Table 81: Masitinib drug profile
Table 82: Masitinib Phase III trial in colorectal cancer
Table 83: Masitinib early-phase data in colorectal cancer
Table 84: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 85: Patients treated with masitinib across the US and five major EU markets, by country, 2016–25
Table 86: Napabucasin drug profile
Table 87: Napabucasin Phase III trial in colorectal cancer
Table 88: Napabucasin Phase III data in colorectal cancer
Table 89: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 90: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016–25
Table 91: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
Table 92: Colorectal cancer five-year survival rates, by stage at diagnosis
Table 93: TNM classification, by stage at diagnosis
Table 94: Leading treatments for colorectal cancer
Table 95: ICD-10 codes for primary sites of colorectal cancer cases
Table 96: Cancer registry databases used as a source of colorectal cancer incidence data, by country
Table 97: Forecasting methodology for colorectal cancer incidence, by country, cancer site, gender, and age group
Table 98: Data sources used for stage distribution of colorectal cancer, by country
Table 99: Sources of survival data used to estimate colorectal cancer prevalence, by country
Table 100: Validation of forecast estimates against benchmark estimates
Table 101: Incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017–37
Table 102: AJCC TNM staging classification
Table 103: Profiled key marketed drugs for colorectal cancer
Table 104: Avastin drug profile
Table 105: Overview of major approvals for Avastin in colorectal cancer
Table 106: Avastin Phase III data in colorectal cancer
Table 107: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 108: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
Table 109: Cyramza drug profile
Table 110: Cyramza Phase III data in colorectal cancer
Table 111: Cyramza Phase I trials in colorectal cancer
Table 112: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 113: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 114: Erbitux drug profile
Table 115: Overview of major approvals for Erbitux in colorectal cancer
Table 116: Erbitux Phase III data in colorectal cancer
Table 117: Erbitux Phase III data in colorectal cancer
Table 118: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 119: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
Table 120: Keytruda drug profile
Table 121: Keytruda Phase III trial in colorectal cancer
Table 122: Keytruda early-phase data in colorectal cancer
Table 123: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 124: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
Table 125: Lonsurf drug profile
Table 126: Lonsurf Phase III data in colorectal cancer
Table 127: Lonsurf Phase II trials in colorectal cancer
Table 128: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 129: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
Table 130: Opdivo drug profile
Table 131: Opdivo pivotal trial data in colorectal cancer
Table 132: Opdivo early-phase trials in colorectal cancer
Table 133: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 134: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
Table 135: Stivarga drug profile
Table 136: Stivarga pivotal trial data in colorectal cancer
Table 137: Stivarga ongoing trials in colorectal cancer
Table 138: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 139: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25
Table 140: TS-1 drug profile
Table 141: TS-1 pivotal trial data in colorectal cancer
Table 142: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
Table 143: Patients treated with TS-1 in Japan, 2016–25
Table 144: Vectibix drug profile
Table 145: Overview of major approvals for Vectibix in colorectal cancer
Table 146: Vectibix pivotal trial data in colorectal cancer
Table 147: Vectibix early-phase data in colorectal cancer
Table 148: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 149: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
Table 150: Zaltrap drug profile
Table 151: Zaltrap pivotal trial data in colorectal cancer
Table 152: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 153: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016–25
Table 154: Profiled pipeline products in development for colorectal cancer
Table 155: Cotellic drug profile
Table 156: Cotellic Phase III trial in colorectal cancer
Table 157: Cotellic early-phase data in colorectal cancer
Table 158: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 159: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
Table 160: OncoVAX drug profile
Table 161: OncoVAX Phase III trial in colon cancer
Table 162: OncoVAX Phase III data in colon cancer
Table 163: OncoVAX sales for colon cancer in the US ($m), 2016–25
Table 164: Patients treated with OncoVAX in the US, 2016–25
Table 165: Tecentriq drug profile
Table 166: Tecentriq Phase III trial in colorectal cancer
Table 167: Tecentriq early-phase data in colorectal cancer
Table 168: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 169: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
Table 170: Binimetinib drug profile
Table 171: Binimetinib Phase III data in colorectal cancer
Table 172: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 173: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
Table 174: Encorafenib drug profile
Table 175: Encorafenib Phase III data in colorectal cancer
Table 176: Encorafenib Phase II data in colorectal cancer
Table 177: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 178: Patients treated with encorafenib across the US and five major EU markets, by country, 2016–25
Table 179: Lefitolimod drug profile
Table 180: Lefitolimod Phase III trial in colorectal cancer
Table 181: Lefitolimod Phase II data in colorectal cancer
Table 182: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 183: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016–25
Table 184: Masitinib drug pro
Table 2: PD-1/PD-L1 colorectal cancer drug sales across the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 3: Colorectal cancer sales across the US, Japan, and five major EU markets, by brand and class ($m), 2016–25
Table 4: Summary of drug classes and molecules included in The authors colorectal cancer patient-based forecast
Table 5: Exchange rates used for calculating prices
Table 6: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
Table 7: Avastin drug profile
Table 8: Overview of major approvals for Avastin in colorectal cancer
Table 9: Avastin Phase III data in colorectal cancer
Table 10: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
Table 12: Cotellic drug profile
Table 13: Cotellic Phase III trial in colorectal cancer
Table 14: Cotellic early-phase data in colorectal cancer
Table 15: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 16: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
Table 17: Cyramza drug profile
Table 18: Cyramza Phase III data in colorectal cancer
Table 19: Cyramza Phase I trials in colorectal cancer
Table 20: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 21: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 22: Erbitux drug profile
Table 23: Overview of major approvals for Erbitux in colorectal cancer
Table 24: Erbitux Phase III data in colorectal cancer
Table 25: Erbitux Phase III data in colorectal cancer
Table 26: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 27: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
Table 28: Keytruda drug profile
Table 29: Keytruda Phase III trial in colorectal cancer
Table 30: Keytruda early-phase data in colorectal cancer
Table 31: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 32: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
Table 33: Lonsurf drug profile
Table 34: Lonsurf Phase III data in colorectal cancer
Table 35: Lonsurf Phase II trials in colorectal cancer
Table 36: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 37: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
Table 38: OncoVAX drug profile
Table 39: OncoVAX Phase III trial in colon cancer
Table 40: OncoVAX Phase III data in colon cancer
Table 41: OncoVAX sales for colon cancer in the US ($m), 2016–25
Table 42: Patients treated with OncoVAX in the US, 2016–25
Table 43: Opdivo drug profile
Table 44: Opdivo pivotal trial data in colorectal cancer
Table 45: Opdivo early-phase trials in colorectal cancer
Table 46: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 47: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
Table 48: Stivarga drug profile
Table 49: Stivarga pivotal trial data in colorectal cancer
Table 50: Stivarga ongoing trials in colorectal cancer
Table 51: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 52: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25
Table 53: TS-1 drug profile
Table 54: TS-1 pivotal trial data in colorectal cancer
Table 55: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
Table 56: Patients treated with TS-1 in Japan, 2016–25
Table 57: Tecentriq drug profile
Table 58: Tecentriq Phase III trial in colorectal cancer
Table 59: Tecentriq early-phase data in colorectal cancer
Table 60: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 61: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
Table 62: Vectibix drug profile
Table 63: Overview of major approvals for Vectibix in colorectal cancer
Table 64: Vectibix pivotal trial data in colorectal cancer
Table 65: Vectibix early-phase data in colorectal cancer
Table 66: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 67: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
Table 68: Zaltrap drug profile
Table 69: Zaltrap pivotal trial data in colorectal cancer
Table 70: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 71: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016–25
Table 72: Binimetinib drug profile
Table 73: Binimetinib Phase III data in colorectal cancer
Table 74: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 75: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
Table 76: Lefitolimod drug profile
Table 77: Lefitolimod Phase III trial in colorectal cancer
Table 78: Lefitolimod Phase II data in colorectal cancer
Table 79: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 80: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016–25
Table 81: Masitinib drug profile
Table 82: Masitinib Phase III trial in colorectal cancer
Table 83: Masitinib early-phase data in colorectal cancer
Table 84: Masitinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 85: Patients treated with masitinib across the US and five major EU markets, by country, 2016–25
Table 86: Napabucasin drug profile
Table 87: Napabucasin Phase III trial in colorectal cancer
Table 88: Napabucasin Phase III data in colorectal cancer
Table 89: Napabucasin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 90: Patients treated with napabucasin across the US, Japan, and five major EU markets, by country, 2016–25
Table 91: Medical oncologists and gastroenterologists surveyed for the colorectal cancer primary research study, 2016
Table 92: Colorectal cancer five-year survival rates, by stage at diagnosis
Table 93: TNM classification, by stage at diagnosis
Table 94: Leading treatments for colorectal cancer
Table 95: ICD-10 codes for primary sites of colorectal cancer cases
Table 96: Cancer registry databases used as a source of colorectal cancer incidence data, by country
Table 97: Forecasting methodology for colorectal cancer incidence, by country, cancer site, gender, and age group
Table 98: Data sources used for stage distribution of colorectal cancer, by country
Table 99: Sources of survival data used to estimate colorectal cancer prevalence, by country
Table 100: Validation of forecast estimates against benchmark estimates
Table 101: Incident cases of colorectal cancer in the US, Japan, and five major EU markets, by country, 2017–37
Table 102: AJCC TNM staging classification
Table 103: Profiled key marketed drugs for colorectal cancer
Table 104: Avastin drug profile
Table 105: Overview of major approvals for Avastin in colorectal cancer
Table 106: Avastin Phase III data in colorectal cancer
Table 107: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 108: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
Table 109: Cyramza drug profile
Table 110: Cyramza Phase III data in colorectal cancer
Table 111: Cyramza Phase I trials in colorectal cancer
Table 112: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 113: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 114: Erbitux drug profile
Table 115: Overview of major approvals for Erbitux in colorectal cancer
Table 116: Erbitux Phase III data in colorectal cancer
Table 117: Erbitux Phase III data in colorectal cancer
Table 118: Erbitux sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 119: Patients treated with Erbitux across the US, Japan, and five major EU markets, by country, 2016–25
Table 120: Keytruda drug profile
Table 121: Keytruda Phase III trial in colorectal cancer
Table 122: Keytruda early-phase data in colorectal cancer
Table 123: Keytruda sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 124: Patients treated with Keytruda across the US, Japan, and five major EU markets, by country, 2016–25
Table 125: Lonsurf drug profile
Table 126: Lonsurf Phase III data in colorectal cancer
Table 127: Lonsurf Phase II trials in colorectal cancer
Table 128: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 129: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
Table 130: Opdivo drug profile
Table 131: Opdivo pivotal trial data in colorectal cancer
Table 132: Opdivo early-phase trials in colorectal cancer
Table 133: Opdivo sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 134: Patients treated with Opdivo across the US and five major EU markets, by country, 2016–25
Table 135: Stivarga drug profile
Table 136: Stivarga pivotal trial data in colorectal cancer
Table 137: Stivarga ongoing trials in colorectal cancer
Table 138: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 139: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25
Table 140: TS-1 drug profile
Table 141: TS-1 pivotal trial data in colorectal cancer
Table 142: TS-1 sales for colorectal cancer in Japan ($m), 2016–25
Table 143: Patients treated with TS-1 in Japan, 2016–25
Table 144: Vectibix drug profile
Table 145: Overview of major approvals for Vectibix in colorectal cancer
Table 146: Vectibix pivotal trial data in colorectal cancer
Table 147: Vectibix early-phase data in colorectal cancer
Table 148: Vectibix sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 149: Patients treated with Vectibix in the US, Japan, and five major EU markets, by country, 2016–25
Table 150: Zaltrap drug profile
Table 151: Zaltrap pivotal trial data in colorectal cancer
Table 152: Zaltrap sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 153: Patients treated with Zaltrap in the US, Japan, and five major EU markets, by country, 2016–25
Table 154: Profiled pipeline products in development for colorectal cancer
Table 155: Cotellic drug profile
Table 156: Cotellic Phase III trial in colorectal cancer
Table 157: Cotellic early-phase data in colorectal cancer
Table 158: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 159: Patients treated with Cotellic in the US and five major EU markets, by country, 2016–25
Table 160: OncoVAX drug profile
Table 161: OncoVAX Phase III trial in colon cancer
Table 162: OncoVAX Phase III data in colon cancer
Table 163: OncoVAX sales for colon cancer in the US ($m), 2016–25
Table 164: Patients treated with OncoVAX in the US, 2016–25
Table 165: Tecentriq drug profile
Table 166: Tecentriq Phase III trial in colorectal cancer
Table 167: Tecentriq early-phase data in colorectal cancer
Table 168: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 169: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
Table 170: Binimetinib drug profile
Table 171: Binimetinib Phase III data in colorectal cancer
Table 172: Binimetinib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 173: Patients treated with binimetinib in the US and five major EU markets, by country, 2016–25
Table 174: Encorafenib drug profile
Table 175: Encorafenib Phase III data in colorectal cancer
Table 176: Encorafenib Phase II data in colorectal cancer
Table 177: Encorafenib sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
Table 178: Patients treated with encorafenib across the US and five major EU markets, by country, 2016–25
Table 179: Lefitolimod drug profile
Table 180: Lefitolimod Phase III trial in colorectal cancer
Table 181: Lefitolimod Phase II data in colorectal cancer
Table 182: Lefitolimod sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 183: Patients treated with lefitolimod across the US, Japan, and five major EU markets, by country, 2016–25
Table 184: Masitinib drug pro
